SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-023135
Filing Date
2021-03-25
Accepted
2021-03-25 21:36:39
Documents
2
Period of Report
2021-03-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 8863
2 POA DOCUMENT poa.txt EX-24.3_975592 2522
  Complete submission text file 0001209191-21-023135.txt   12832
Mailing Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022
Business Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022 212-739-6451
Edgewise Therapeutics, Inc. (Issuer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902
Business Address
Edris Badreddin (Reporting) CIK: 0001786966 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40236 | Film No.: 21774382